MacroGenics Inc (MGNX) stock

MGNXNasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 4/30

$2.20−0.09 (-3.93%)

Close on Nov 13, 2026Market cap $140.14MP/E –Yield –

MacroGenics gross margin

Gross margin is gross profit as a percentage of revenue.

MacroGenics's gross margin for the twelve months ending Dec 31, 2025 was 100.0%. For fiscal 2025 it was 100.0%, against 99.4% the year before. The highest annual figure on record is 100.0% in fiscal 2019.

Annual gross margin

Period	Period end	Value	Change (pts)
FY2025	Dec 31, 2025	100.0%	+0.6
FY2024	Dec 31, 2024	99.4%	+0.5
FY2023	Dec 31, 2023	98.9%	+1.2
FY2022	Dec 31, 2022	97.8%	+1.2
FY2021	Dec 31, 2021	96.6%	−3.4
FY2020	Dec 31, 2020	100.0%	+0.0
FY2019	Dec 31, 2019	100.0%	–

Quarterly gross margin

Change is against the same quarter a year earlier.

Period	Period end	Value	Change (pts)
Q4 FY2025	Dec 31, 2025	100.0%	+1.2
Q3 FY2025	Sep 30, 2025	100.0%	+0.2
Q2 FY2025	Jun 30, 2025	100.0%	+1.6
Q1 FY2025	Mar 31, 2025	100.0%	+3.0
Q4 FY2024	Dec 31, 2024	98.8%	+0.3
Q3 FY2024	Sep 30, 2024	99.8%	+0.7
Q2 FY2024	Jun 30, 2024	98.4%	+0.3
Q1 FY2024	Mar 31, 2024	97.0%	−2.5
Q4 FY2023	Dec 31, 2023	98.5%	−1.4
Q3 FY2023	Sep 30, 2023	99.2%	+6.4
Q2 FY2023	Jun 30, 2023	98.0%	−1.3
Q1 FY2023	Mar 31, 2023	99.5%	−0.0
Q4 FY2022	Dec 31, 2022	99.8%	+6.5
Q3 FY2022	Sep 30, 2022	92.8%	+3.4
Q2 FY2022	Jun 30, 2022	99.3%	−0.6
Q1 FY2022	Mar 31, 2022	99.6%	−0.3
Q4 FY2021	Dec 31, 2021	93.3%	−6.7
Q3 FY2021	Sep 30, 2021	89.4%	−10.6
Q2 FY2021	Jun 30, 2021	99.9%	−0.1
Q1 FY2021	Mar 31, 2021	99.9%	−0.1
Q4 FY2020	Dec 31, 2020	100.0%	–
Q3 FY2020	Sep 30, 2020	100.0%	–
Q2 FY2020	Jun 30, 2020	100.0%	–
Q1 FY2020	Mar 31, 2020	100.0%	–